Search Results

• Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones • Company expects to complete early market access regulatory approval submissions for Herlystic™ (“OST-HER2" or “daznelimgene lisbac”) in the U.S., U.K., Europe and Australia in the fourth quarter of 2026

New facility in Namie will leverage NovAccel’s proprietary compact superconducting accelerator technology to support reliable, commercial-scale Ac-225 production

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.

Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.